Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1 (currently amended): A ~~serine protease inhibitor~~ compound of formula (I)



(I)

where R_2 represents

(i) phenyl optionally being substituted in the 3 and/or 4 position by halo, nitro, thiol, haloalkoxy, hydrazido, alkylhydrazido, amino, haloalkyl, alkylthio, alkenyl, alkynyl, acylamino, tri or difluoromethoxy, carboxy, acyloxy, $MeSO_2$- or R_1, and optionally substituted at the 6 position by amino, hydroxy, halo, alkyl, carboxy, alkoxycarbonyl, cyano, amido, aminoalkyl, alkoxy or alkylthio; or

(ii) naphth-2-yl optionally substituted at the 6 or 7 position by halo, haloalkoxy, haloalkyl, cyano, nitro, amino, hydrazido, alkylthio, alkenyl, alkynyl or R_{1j} and optionally substituted at the 3 position by amino, hydroxy, halo, alkyl, carboxy, cyano, amido, aminoalkyl, alkoxy or alkylthio;

-X-X- is CONH;

R_{1j} ~~R_{1a}~~ represents hydrogen or hydroxyl, alkoxy, alkyl, aminoalkyl, hydroxyalkyl, alkoxyalkyl, alkoxycarbonyl, alkylaminocarbonyl, alkoxycarbonylamino, acyloxymethoxycarbonyl or alkylamino optionally substituted by hydroxy, alkylamino, alkoxy, oxo, aryl or cycloalkyl;

R_1 is as defined for R_{1j} ~~R_{1a}~~, provided that R_1 is not unsubstituted aminoalkyl;

L is ~~CO, CH_2NH, $CONR_{1d}(CH_2)_m$, $(CH_2)_mN(R_{1d})CO(CH_2)_m$, $(CH_2)_{m+2}$, $CO(CH_2)_m$, $(CH_2)_mCO$, $(CH_2)_mOC{=}O$, $(CH_2)_mO$, $CH{=}CH(CH_2)_m$, SO_2, SO_2NR_{1d}, $SO_2(CH_2)_m$, $(CH_2)_mSO_2$ or $(CH_2)_mSO_2NR_{1d}$ (where each m is independently 0 or 1 and R_{1d} is hydrogen)~~;

Y is a CH group;

Cy is a saturated or unsaturated, mono or poly cyclic, homocyclic group optionally substituted by groups R_{3a} or phenyl optionally substituted by R_{3a};

each R_{3a} independently is R_{1c}, amino, halo, cyano, nitro, thiol, alkylthio, alkylsulphonyl, alkylsulphenyl, triazolyl, imidazolyl, tetrazolyl, hydrazido, alkyl imidazolyl, thiazolyl, alkyl thiazolyl, alkyl oxazolyl, oxazolyl, alkylsulphonamido, alkylaminosulphonyl, aminosulphonyl, haloalkoxy and haloalkyl;

$Lp(D)_n$ ~~Lp~~ is a lipophilic organic group selected from



Serial No. 09/926,712
Response to Office Action of January 14, 2004



Serial No. 09/926,712
Response to Office Action of January 14, 2004



Serial No. 09/926,712
Response to Office Action of January 14, 2004



Serial No. 09/926,712
Response to Office Action of January 14, 2004



Serial No. 09/926,712
Response to Office Action of January 14, 2004



wherein R_3 is as defined for R_{3a};

~~m represents 0 or 1;~~

R_4 represents hydrogen, $(CH_2)_wCOOH$ or $(CH_2)_wCONH_2$;

w represents an integer from 0 to 4; and

when X is in the ring bonded to L, X is N and, otherwise X represents CH or N;

~~D is a hydrogen bond donor group; and n is 0;~~

~~or -L-Lp(D)$_n$ is:~~

~~(i)~~



~~in which q is 1 or 2;~~

~~Q is a direct bond; and R_q is piperidin-4-yl which may bear a C_{1-3}alkyl substituent at the 1 position; or R_q is NR_aR_b in which each of R_a and R_b independently is hydrogen or C_{1-3}alkyl; or one of R_a and R_b is hydrogen or methyl and the other of R_a and R_b is $-CH_2-R_c$ or CH_2-R_d in which R_c is pyridyl or phenyl (which phenyl may bear a fluoro, chloro, methyl, $CONH_2$, SO_2NH_2, methylaminosulphonyl, dimethylaminosulphonyl, methylsulphonylamino, methoxy or methylsulphonyl substituent) and in which R_d is isopropyl or cyclopentyl, or NR_aR_b is pyrrolidino, piperidino, morpholino, piperazino, or tetrahydro-1,4-diazepino in which a pyrrolidino or piperidino may be a 3,4 didehydro derivative and in which a pyrrolidino, piperidino, piperazino, or tetrahydro-1,4-diazepino may bear a methyl group at the 4-position;~~

~~(ii)~~



~~in which R_t is phenyl (which phenyl may bear a fluoro, chloro, C_{1-4} alkyl, methoxy or methylsulphonyl substituent), or~~

~~(iii)~~



~~in which Het is a divalent 5-membered heteroaromatic group containing 1, 2 or 3 heteroatoms selected from O, N and S and having the two ring atoms at which it is connected separated by one ring atom;~~

~~h is 0 or 1; and~~

~~R_h is phenyl which may bear one or more R_3 substituents;~~

and

R_{1c} is ~~and R_{1j} are~~ as defined for $R_{1j}R_{1a}$,

or a physiologically tolerable salt thereof.

2 (canceled):

3 (canceled):

4 (canceled):

5 (canceled):

6 (currently amended): A compound as claimed in Claim 1, in which Y ~~is a CH group and~~ has the conformation that would result from construction from a D-α-aminoacid NH_2-CH(Cy)-COOH where the NH_2 represents part of X-X.

7 (canceled):

8 (previously presented): A compound as claimed in Claim 1, in which Cy represents an optionally R_{3a} substituted phenyl, naphthyl or cycloalkyl group.

9 (original): A compound as claimed in Claim 8, in which R_{3a} is selected from hydrogen, hydroxyl, methoxy, ethoxy, methyl, ethyl, methylaminomethyl, dimethylaminomethyl, hydroxymethyl, carboxy, methoxymethyl, methoxycarbonyl, ethoxycarbonyl, methylaminocarbonyl, dimethylamino-carbonyl, aminomethyl, $CONH_2$, CH_2CONH_2, acetylamino, methoxycarbonylamino, ethoxycarbonylamino, t-butoxycarbonylamino, amino, fluoro, chloro, cyano, nitro, thiol, methylthio, methylsulphonyl, ethylsulphonyl, methylsulphenyl, methylsulphonylamido, ethylsulphonylamido, methylaminosulphonyl, ethylaminosulphonyl, aminosulphonyl, trifluoromethoxy and trifluoromethyl.

10 (previously presented): A compound as claimed in Claim 1, in which Cy is phenyl, 4-aminophenyl, 4-amidophenyl, 4-(N-methyl)amidophenyl, 4-(N,N-dimethyl)amidophenyl, 2-chlorophenyl, 2-methylphenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 4-hydroxphenyl, 2-methoxyphenyl, 4-methoxy-phenyl, 4-carboxyphenyl, 3-ethylsulphonylaminophenyl, cyclohexyl or naphth-1-yl.

11 (canceled):

12 (canceled):

13 (canceled):

14 (canceled):

15 (canceled):

16 (withdrawn):

17 (withdrawn):

18 (withdrawn):

19 (previously presented): A compound as claimed in Claim 1, in which R_3 is selected from hydrogen, hydroxyl, methoxy, ethoxy, methyl, ethyl, propyl, 2-propyl, butyl, 2-butyl, t-butyl, pentyl, 2-pentyl or 3-pentyl, isopropylaminomethyl, dimethylaminomethyl, diethylaminomethyl, dimethylaminoethyl, acetyl, hydroxymethyl, hydroxyethyl, carboxy, methoxymethyl, methoxycarbonyl, ethoxycarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, aminomethyl, aminocarbonyl, methylamino, dimethylamino, ethylamino, formylamino, acetylamino, amino, fluoro, chloro, cyano, nitro, thiol, methylthio, methylsulphonyl, ethylsulphonyl, isopropylsulphonyl, methylsulphenyl, 1,2,4-triazol-2-yl, 1,2,4-triazol-4-yl, 1,2,3-triazol-4-yl, 1,3-imidazol-1-yl or 1,3-imidazol-4-yl, tetrazol-1-yl, tetrazol-5-yl; methylsulphonamido, ethylsulphonamido, propylsulphonamido, methylaminosulphonyl, ethylaminosulphonyl, propylaminosulphonyl, aminosulphonyl, trifluoromethoxy, trifluoromethyl and trichloromethyl.

20 (currently amended): A compound as claimed in Claim 1, in which Lp is selected from



and

where R_8 represents H, OMe, SO_2Me, F, cyano, amido, amino, NO_2, Cl or OH.

21 (previously presented): A compound as claimed in Claim 1, in which Lp represents



(K)

wherein X_2 is halo, hydrogen, amino, nitro or $CONH_2$.

22 (canceled):

23 (previously presented): A compound as claimed in Claim 1, in which R_2 represents:

(i) phenyl optionally being substituted in the 3 and/or 4 position by fluoro, chloro, bromo, iodo, nitro, difluoromethoxy, trifluoromethoxy, amino, trifluoromethyl, methylthio, vinyl, carboxy, acetoxy, $MeSO_2-$, hydroxy, methoxy, ethoxy, methyl, methoxycarbonyl, methylamino, ethylamino or

amido, and optionally substituted at the 6 position by amino, hydroxy, fluoro, methoxycarbonyl, cyano or aminomethyl; or

(ii) naphth-2-yl optionally substituted at the 6, position by hydroxy and optionally substituted at the 3 position by amino or hydroxy.

24 (canceled):

25 (canceled):

26 (canceled):

27 (original): A pharmaceutical composition, which comprises a compound as claimed in Claim 1 together with at least one pharmaceutically acceptable carrier or excipient.

28 (previously presented): A compound as claimed in Claim 23, in which R_2 represents phenyl substituted in the 4 position by chloro, amino, vinyl, methylamino, methyl or methoxy, optionally at the 3 position with amino or hydroxy, and optionally at the 6 position with amino or hydroxy.

29 (canceled):

30 (canceled):

31 (canceled):

32 (canceled):

33 (canceled):

34 (canceled):

35 (canceled):

36 (canceled):

37 (canceled):

38 (canceled):

39 (canceled):

40 (canceled):

41 (canceled):

42 (currently amended): A compound as claimed in Claim 1, which is selected from:
1-(3-Amino-4-chlorobenzoyl-D-phenylglycinyl)-4-(4-fluoro-2-methylsulphonylphenyl)piperazine;
~~1-(3-Amino-4-chlorobenzoyl-D-phenylglycinyl)-1'-methyl-4,4'-bispiperidine;~~
1-(3-Amino-4-chlorobenzoyl-D-phenylglycinyl)-4-(2-methylsulphonylphenyl)piperazine;
and physiologically tolerable salts thereof.

43 (previously presented): A pharmaceutical composition, which comprises a compound as claimed in Claim 42 together with at least one pharmaceutically acceptable carrier or excipient.